{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:46:23Z","timestamp":1790401583263,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While multiple studies report that the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (BNT162b2 XBB vaccine) is effective in preventing COVID-19 hospitalisation and death, effectiveness beyond six months remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extended our previous study of BNT162b2 XBB vaccine effectiveness (VE) to evaluate durability against JN.1-related hospitalisation up to 46 weeks since dose using the id.DRIVE platform across Europe. This multi-country, multi-centre test-negative case-control study assessed the effectiveness and durability of the BNT162b2 XBB vaccine in preventing JN.1-associated hospitalisation among adults with severe acute respiratory infection between October 2023 and August 2024. Each case was matched with up to four controls by symptom onset date and study site. Multivariable analyses were adjusted for symptom onset date, age, sex, number of chronic conditions, and influenza vaccination receipt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 827 test-positive cases and 2232 test-negative controls, protection against hospitalisation was sustained from two to &lt;30 weeks since dose, with evidence of significant waning thereafter. VE was 64.5% (95% CI: 56.6; 71.0) at two to &lt;30 weeks, and 4.9% (95% CI: \u221230.3; 30.7) at 30 to &lt;46 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalisation for up to 30 weeks. Protection against hospitalisation was non-significant after 30 weeks since dose, potentially due to further shift in circulating SARS-CoV-2 strains and\/or waning immunity. Given the high COVID-19 activity in Europe during summer 2024, an additional vaccination after six months is warranted for those at risk of COVID-19 hospitalisation to maintain year-round protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342382","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:25:27Z","timestamp":1770834327000},"page":"e0342382","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-9641","authenticated-orcid":true,"given":"Hannah R.","family":"Volkman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-2032","authenticated-orcid":true,"given":"Leonie","family":"de Munter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-8302","authenticated-orcid":true,"given":"Thao M. P.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Mitratza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1tia","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Valluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-0815","authenticated-orcid":true,"given":"Andr\u00e9s","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Conde-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Drikite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-3741","authenticated-orcid":true,"given":"Beate","family":"Gr\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Icardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit Luit","family":"ten Kate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Mira-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Orrico-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Otero-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaatje","family":"Bollaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"pone.0342382.ref001","unstructured":"EMA. Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5. https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-ema-recommends-approval-adapted-covid-19-vaccine-targeting-omicron-xbb15. 2023. Accessed 2024 July 24."},{"issue":"2","key":"pone.0342382.ref002","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00746-6","article-title":"Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study","volume":"24","author":"CH Hansen","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pone.0342382.ref003","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13292","article-title":"Effectiveness of XBB.1.5 monovalent COVID-19 vaccines during a period of XBB.1.5 dominance in EU\/EEA countries, october to november 2023: A VEBIS-EHR Network Study","volume":"18","author":"S Monge","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"pone.0342382.ref004","doi-asserted-by":"crossref","first-page":"2300703","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300703","article-title":"Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023","volume":"29","author":"CH van Werkhoven","year":"2024","journal-title":"Euro Surveill"},{"issue":"8","key":"pone.0342382.ref005","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamainternmed.2024.1640","article-title":"Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19","volume":"184","author":"SY Tartof","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"19","key":"pone.0342382.ref006","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1016\/j.vaccine.2024.05.067","article-title":"Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024","volume":"42","author":"C Laniece Delaunay","year":"2024","journal-title":"Vaccine"},{"issue":"10","key":"pone.0342382.ref007","doi-asserted-by":"crossref","first-page":"2400109","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400109","article-title":"Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024","volume":"29","author":"AJ Huiberts","year":"2024","journal-title":"Euro Surveill"},{"key":"pone.0342382.ref008","unstructured":"UKHSA. COVID-19 vaccine surveillance report (week 17). 2024. https:\/\/assets.publishing.service.gov.uk\/media\/662a43ed55e1582b6ca7e5ec\/Vaccine_surveillance_report_2024_week_17.pdf"},{"issue":"1","key":"pone.0342382.ref009","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1038\/s41467-024-53842-w","article-title":"Effectiveness of BNT162b2 XBB vaccine in the US veterans affairs healthcare system","volume":"15","author":"AR Caffrey","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"pone.0342382.ref010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciae132","article-title":"Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine","volume":"79","author":"NK Shrestha","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0342382.ref011","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae370","article-title":"Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages","volume":"11","author":"SY Tartof","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"pone.0342382.ref012","doi-asserted-by":"crossref","first-page":"102995","DOI":"10.1016\/j.eclinm.2024.102995","article-title":"Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform","volume":"79","author":"JL Nguyen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"pone.0342382.ref013","article-title":"Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine against the JN.1 Variant","author":"NK Shrestha","year":"2024","journal-title":"openRxiv"},{"issue":"11","key":"pone.0342382.ref014","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70009","article-title":"Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024","volume":"18","author":"L Merdrignac","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"12","key":"pone.0342382.ref015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49944","article-title":"BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age","volume":"7","author":"SY Tartof","year":"2024","journal-title":"JAMA Netw Open"},{"key":"pone.0342382.ref016","doi-asserted-by":"crossref","first-page":"126881","DOI":"10.1016\/j.vaccine.2025.126881","article-title":"Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states","volume":"52","author":"KM Andersen","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"pone.0342382.ref017","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2024.2428800","article-title":"Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86\/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study","volume":"23","author":"B Nunes","year":"2024","journal-title":"Expert Review of Vaccines"},{"key":"pone.0342382.ref018","unstructured":"UKHSA. COVID-19 vaccine surveillance report (week 29). UKHSA. 2024. https:\/\/assets.publishing.service.gov.uk\/media\/669923b20808eaf43b50d1fd\/Vaccine_surveillance_report_2024_week_29.pdf"},{"issue":"5","key":"pone.0342382.ref019","doi-asserted-by":"crossref","first-page":"106461","DOI":"10.1016\/j.jinf.2025.106461","article-title":"Understanding the effectiveness of the Comirnaty monovalent and bivalent vaccines during the Winter Coronavirus (COVID-19) Infection Study","volume":"90","author":"T Ward","year":"2025","journal-title":"Journal of Infection"},{"key":"pone.0342382.ref020","article-title":"Effectiveness of XBB.1.5 Vaccines Against Omicron Subvariants","author":"D-Y Lin","year":"2024","journal-title":"openRxiv"},{"key":"pone.0342382.ref021","unstructured":"ERVISS Dashboard. https:\/\/erviss.org\/. Accessed 2025 January 10."},{"issue":"1","key":"pone.0342382.ref022","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"D Planas","year":"2024","journal-title":"Nat Commun"},{"issue":"8047","key":"pone.0342382.ref023","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"F Jian","year":"2025","journal-title":"Nature"},{"key":"pone.0342382.ref024","unstructured":"CDC. COVID-19 can surge throughout the year 2024. https:\/\/www.cdc.gov\/ncird\/whats-new\/covid-19-can-surge-throughout-the-year.html. Accessed 2025 January 10."},{"key":"pone.0342382.ref025","unstructured":"WHO. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic. Accessed 2025 January 10."},{"key":"pone.0342382.ref026","unstructured":"ECDC. ECDC technical report: Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0. 2021. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Core-protocol-for-ECDC-studies-of-COVID-19-vaccine-effectiveness-against-hospitalisation-with-SARI.pdf"},{"key":"pone.0342382.ref027","unstructured":"EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants. https:\/\/www.ema.europa.eu\/en\/news\/ema-and-ecdc-statement-updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants. 2023. Accessed 2024 July 24."},{"issue":"1","key":"pone.0342382.ref028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"K-Y LIANG","year":"1986","journal-title":"Biometrika"},{"issue":"1","key":"pone.0342382.ref029","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","article-title":"Longitudinal data analysis for discrete and continuous outcomes","volume":"42","author":"SL Zeger","year":"1986","journal-title":"Biometrics"},{"key":"pone.0342382.ref030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.32614\/RJ-2017-030","article-title":"PGEE: an R Package for analysis of longitudinal data with high-dimensional covariates","volume":"9","author":"G Inan","year":"2017","journal-title":"R J"},{"issue":"6","key":"pone.0342382.ref031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17402","article-title":"Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults","volume":"8","author":"R Link-Gelles","year":"2025","journal-title":"JAMA Netw Open"},{"key":"pone.0342382.ref032","volume-title":"Handbook of latent variable and related models","author":"SY Lee","year":"2007"},{"key":"pone.0342382.ref033","volume-title":"R: A Language and Environment for Statistical Computing","author":"R-Core-Team","year":"2021"},{"key":"pone.0342382.ref034","unstructured":"ECDC. Communicable disease threats report (Week 53; 28 December 2024 \u2013 3 January 2025). 2025. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/communicable-disease-threats-report-week-53-2024.pdf"},{"key":"pone.0342382.ref035","article-title":"Effectiveness of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 omicron XBB and BA.2.86\/JN.1 lineage hospitalization and a comparison of clinical severity-IVY network, 26 Hospitals, October 18, 2023-March 9, 2024","author":"KC Ma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0342382.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325269","article-title":"Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up","volume":"20","author":"S Carazo","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"pone.0342382.ref037","article-title":"Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors","volume":"75","author":"MK Doll","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pone.0342382.ref038","doi-asserted-by":"crossref","unstructured":"Mustapha M, Togo K, Volkman HR, Yang J, Yehoshua A, Fusco MD, et al. Under-reporting of SARS-CoV-2 infections in 27 countries, 2020\u20132022. 2024. https:\/\/dx.doi.org\/10.2139\/ssrn.5014145","DOI":"10.2139\/ssrn.5014145"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:25:32Z","timestamp":1770834332000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342382"}},"subtitle":[],"editor":[{"given":"Haihai","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342382","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}